Abstract
Objectives: It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining 50 copies/mL after baseline, and the time to virological rebound was calculated using the Kaplan-Meier method. Results: There were 739 eligible patients; 446 (60.4%) had HIV RNA 3 per year versus +21.2 (22.5, 53.2)cells/mm3 per year; P1/40.036. Conclusions: Residual viraemia assessed by kPCR was not associated with virological rebound during 1 year of follow-up. However, the patients attaining
| Original language | English |
|---|---|
| Pages (from-to) | 213-217 |
| Number of pages | 5 |
| Journal | Journal of Antimicrobial Chemotherapy |
| Volume | 67 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2012 |
Fingerprint
Keywords
- Antiretroviral therapy
- HIV-1 viral load
- Immune recovery
- kPCR
- Virological failure
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
- Medicine(all)
Cite this
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. / Gianotti, Nicola; Galli, Laura; Racca, Sara; Salpietro, Stefania; Cossarini, Francesca; Spagnuolo, Vincenzo; Barda, Beatrice; Canducci, Filippo; Clementi, Massimo; Lazzarin, Adriano; Castagna, Antonella.
In: Journal of Antimicrobial Chemotherapy, Vol. 67, No. 1, 2012, p. 213-217.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL
AU - Gianotti, Nicola
AU - Galli, Laura
AU - Racca, Sara
AU - Salpietro, Stefania
AU - Cossarini, Francesca
AU - Spagnuolo, Vincenzo
AU - Barda, Beatrice
AU - Canducci, Filippo
AU - Clementi, Massimo
AU - Lazzarin, Adriano
AU - Castagna, Antonella
PY - 2012
Y1 - 2012
N2 - Objectives: It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining 50 copies/mL after baseline, and the time to virological rebound was calculated using the Kaplan-Meier method. Results: There were 739 eligible patients; 446 (60.4%) had HIV RNA 3 per year versus +21.2 (22.5, 53.2)cells/mm3 per year; P1/40.036. Conclusions: Residual viraemia assessed by kPCR was not associated with virological rebound during 1 year of follow-up. However, the patients attaining
AB - Objectives: It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining 50 copies/mL after baseline, and the time to virological rebound was calculated using the Kaplan-Meier method. Results: There were 739 eligible patients; 446 (60.4%) had HIV RNA 3 per year versus +21.2 (22.5, 53.2)cells/mm3 per year; P1/40.036. Conclusions: Residual viraemia assessed by kPCR was not associated with virological rebound during 1 year of follow-up. However, the patients attaining
KW - Antiretroviral therapy
KW - HIV-1 viral load
KW - Immune recovery
KW - kPCR
KW - Virological failure
UR - http://www.scopus.com/inward/record.url?scp=84859178656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859178656&partnerID=8YFLogxK
U2 - 10.1093/jac/dkr422
DO - 10.1093/jac/dkr422
M3 - Article
C2 - 21987242
AN - SCOPUS:84859178656
VL - 67
SP - 213
EP - 217
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
SN - 0305-7453
IS - 1
ER -